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Amyloid Diseases: A Truly
Emergent Phenomenon
The primary goal of the study of com-
plex adaptive matter is to identify the key
organizing principles that govern mate-
rials phenomena at given length and time
scales. In the case of the folding of indi-
vidual globular proteins into their func-
tional structures, we know a great deal.
For example, the local rules governing α-
helical secondary structure have been un-
derstood in detail for some 40 years;1,2
indeed, the α-helix was predicted by Paul-
ing and collaborators prior to discovery.3
For the global tertiary structure of the pro-
tein, extensive experiments and simula-
tion studies show that proteins engineered
by evolution to experience minimal frus-
tration in the interactions between closely
contacted amino acids (or residues) de-
velop funneled energy landscapes and rel-
atively rapid (and multiple) pathways to
folding after synthesis.4 As discussed in
the article by Ramirez in this issue, “frus-
tration’’ refers to the effect of competing
interactions that make it impossible to fa-
vorably lower the interaction energy.
However, we have comparatively little
understanding of the organizing princi-
ples governing structure formation for
proteins interacting with other proteins or
membranes. This lack of knowledge is
problematic, because proteins left alone
tend to spontaneously aggregate, often by
formation of β-sheet structures, which are
not governed by local formation rules like
α-helices (the distances between hydro-
gen bonding residues along the backbone
can be great). β-sheets are formed from
approximately linear stretches of peptide
that hydrogen-bond from line to line.
These structures are especially prone to
protein aggregation due to favorable
edge-to-edge hydrogen bonding between
sheets.5 This aggregation tendency is an
obstacle in high-throughput proteomics,
where one is interested in measuring the
properties of individual proteins.6
Purposeful biological aggregation of
monomeric proteins, as in the assembly of
actin filaments or microtubules,7 is usually
highly regulated and energetically con-
trolled (we will discuss tightly controlled
and biologically useful β-sheet self-
assembly later in the article). Living 
organisms have evolved an effective
quality-control system to prevent protein
misfolding and aggregation, where chap-
erone proteins provide “safe houses” for
folding proteins,8 and the ubiquitin/pro-
teosome system ensures rapid degrada-
tion or disposal of misfolded proteins.
Table I conveys the tragic side of uncon-
trolled β-sheet self-assembly: it summa-
rizes the key aspects of seven (out of
dozens) prominent human amyloid dis-
eases. Amyloid means “starch-like”—the
aggregates stain like starch. These dis-
eases typically arise in old- or middle-
aged populations, and frequently arise
spontaneously or sporadically rather than
from genetic predisposition. Indeed, for
spontaneous Alzheimer’s, Parkinson’s,
prion, and immunoglobulin light chain
diseases, incidence varies little between
countries. Moreover, prion diseases, the
lone infectious type of amyloid disease,
show highly reproducible dose-versus-
incubation-time distributions for inter-
cerebrally inoculated animals.9 Remarkably,
infectious protein-only prion aggregates
have been grown in vitro,10 proving that
the protein interaction properties alone,
without additional biochemical guidance,
account for the disease.
These observations suggest that these
diseases can be studied from the perspec-
tive of materials growth, without exten-
sive biological modulation. Indeed, it
appears that the growth of amyloid struc-
ture has much in common with the ori-
ented aggregation of inorganic, nearly
monodispersed nanoparticles.11 We seek
here to portray the growing scientific
movement toward the use of concepts and
tools from materials science in the study of
amyloidogenic proteins to elucidate the
mechanisms of disease and design new
materials.
Amyloid Structures: Plaques,
Protein Nanotubes, and Oligomers
Plaques
The extracellular and/or intracellular
accumulation of amyloid fibrils in the
form of plaques or inclusions (Lewy bod-
ies) in the brain is a defining hallmark for
several neurodegenerative diseases (Fig-
ure 1). For example, Alzheimer’s disease
patients have large quantities of postmortem
brain plaques, predominantly composed
of 40–42-amino-acid-long Aβ peptides
that are cleaved by protease proteins from
the Alzheimer’s precursor protein (BAPP).13
These micrometer-scale plaques are com-
posed of multi-polymeric strands of the
peptide, called fibrils (Figure 1e), which
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have high quantities of β-sheet structure
as revealed by crystallography, circular
dichroism (which detects the different
light polarization rotation tendencies of α-
helices and β-sheets), and more recently,
solid-state magnetic resonance studies.
These β-strands are aligned perpendicular
to the fibrillar axis, in a so-called “cross-β”
structure, shown in Figure 1f. Postmortem
plaques and inclusions from a variety of
diseases are shown in Figure 1.13 We note
that the amyloid fibrils are protein nano-
tubes, hollow in the middle, with diame-
ters of the order of 10–20 nm.
Despite a dominant research focus on
both structure measurements and com-
puter modeling on plaques, an emerging
perspective is that the plaques may repre-
sent disease end points having little to do
with toxicity.14 This view is supported by
observations such as (1) the abundant Aβ
plaques observed in the brains of individ-
uals displaying no symptoms of Alzheimer’s
disease and (2) the non-uniformity of
plaque observation in prion diseases: for ex-
ample, victims of kuru (a disease among
the Fore people of New Guinea, arising
from ritual cannibalism of deceased tribe
members) exhibit them, while victims of
spontaneous Creutzfeldt-Jakob disease
usually do not.15 In this view, toxicity 
is engendered by small β-sheet aggre-
gates, possibly on the pathway to amyloid 
fibrils.
β-Helices
Accordingly, attention has turned to
small β-sheet motifs with multiple assem-
bly outcomes, especially the left-handed
β-helix (LHBH) structures shown in Fig-
ure 2,16 recently proposed as the β-sheet
unit for infectious mammalian prion
trimers on the basis of cryogenic electron
microscopic data.17 The LHBH β-sheet
structure has also been proposed for yeast
prion-like proteins,18 Alzheimer’s disease,19
and Huntington’s disease.16,20 This LHBH
motif was first observed in several bacter-
ial enzymes and the “antifreeze” protein
of the spruce budworm; to date, there are
11 structures in the protein data bank
(http://www.rcsb.org/pdb/) confirmed 
to have LHBHs. LHBHs are usually pre-
sumed (or, in two cases, observed)21,22 to be
in protein trimers. The LHBH motif has a
fundamental repeat unit of triangular
cross section, consisting of 18 amino acids
with two per bend region and four per 
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Table I: Aspects of Some Human Amyloid Diseases with Associated Protein Aggregation.
Heritable Onset Age*
Disease Protein/Peptide Function Component Incidence (Years) 
Alzheimer’s51 β-42 (from BAPP) and τ ? !25% !50% of post-85-yr-old !65
population
Parkinson’s52 α-synuclein ? 5–10% !1% of post-50-yr-old 55–60 yrs
population
Huntington’s23 huntingtin ? 100% 1 in 20,000 (Caucasian) 35–40
Familial ALS Superoxide dismutase Lowers oxidative 100% (5–10% of 2 in 106 46
(Lou Gehrig’s (20% of cases) stress all ALS)
disease)53
Type II diabetes54 IAPP ? High (obesity 14 106 per year (U.S.) !40
trigger)
Immunoglobulin IG light chain Immune response Small/unknown 1 in 105 64
light chain55 
Prion diseases35 PrPc Lowers oxidative 10–15% !1 in 106 63
stress?
*Incidence/onset age is for non-heritable sporadic disease, unless otherwise noted.
"
Figure 1. Plaques and fibrils. (a)–(d) Postmortem tissue plaques from human amyloid
disease patients (from Reference 13): (a) Aβ42 (Alzheimer’s) plaque, (b) α-synuclein
(Parkinson’s) plaque, (c) huntingtin plaque (Huntington’s disease), and (d) PrPSc (kuru)
plaque. (e) Transmission electron microscope images of amyloid fibrils (H. Lashuel,
unpublished data). (f) Model of a hollow-core SH3 domain fibril: upper panel shows a
density map cross section, lower panel shows the cross-β structure.56
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β-strand, alternating between hydropho-
bic and hydrophilic in the strand. The 
triangular cross section is very uniform
across observed LHBHs (Figure 2c); 
each edge is !1.9 nm in length. In Fig-
ure 2d, we show how multiple copies 
of the LHBH of an enzyme from E. coli
(labeled 1FWY on the protein data base 
at www.rcsb.org/pdb) can be assembled
into a kind of β-nanotube. This raises 
the natural and intriguing question: 
are amyloid fibrils composed of such
“nanofilaments”?19
The LHBH has a tantalizing connection
to Huntington’s and other polyglutamine
repeat diseases, where pathology derives
from an inherited excess number of re-
peats of the amino acid glutamine on one
end (the N-terminus) of the huntingtin
protein.23 A polyglutamine repeat number
p of less than !24 is normal; for p ! 36,
disease is certain. Note that 36 is the num-
ber of amino acids or residues in two turns
of a LHBH that has fully saturated inter-
nal hydrogen bonds.19
The LHBH presents a challenge to 
theory and simulation. At present, this
motif has not emerged from any molecu-
lar dynamics simulations or semi-analytic
(Hamiltonian or cellular automata) ap-
proaches. The complicating factor is the
long-range coupling along the backbone
(bonded amino acids are separated by 18
residues). On the other hand, the remark-
able conservation of the shape and helical
cross section suggest that this is a motif
ripe for study. 
Nanoscale Oligomers
β-sheet oligomers obtained from in vitro
growth of aggregates have been studied
extensively.13 One common form seems to
be a spherical micelle-like aggregate of β-
converted proteins, which have been im-
plicated as precursors for the chain-like
(protofibril) and annular oligomers that
are also seen frequently during in vitro
amyloid formation by most amyloido-
genic proteins.24 Figure 3 shows a com-
pendium of oligomers and protofibrils
from amyloid disease proteins.25,26 The an-
nular oligomers underlie the proposed
toxicity mechanism discussed later in this
article. We note that all atomic force micro-
scope (AFM) measurements of spherical,
chain-like, and annular oligomers share
the same height and diameter, suggesting
that the spherical aggregates are the pre-
cursors to the larger chain and annular
pore-like structures.
The diversity of pre-fibrillar oligomer
structures, the formation of which are
highly dependent upon protein sequence
and environmental conditions (e.g., pH,
salt concentration, and levels of molecular
crowding), may explain the mystery of
prion disease strains. Strains, for a given
mammal, have unique incubation-time
versus dose distributions, tissue lesion pro-
files, and distributions of post-translationally
attached sugars: the prion protein can
have 0, 1, or 2 sugars attached.27,28 More-
over, strains breed true upon multiple
passage in animals. This means that upon
passage from a diseased animal to a
healthy animal, the same properties (incu-
bation time, lesion profile, sugar binding)
are preserved. There is considerable evi-
dence that strain is encoded in prion con-
formation but no detailed understanding
of the underlying mechanisms.27,28 Prion
oligomers17 might have a spectrum of dif-
ferent shapes, and oriented aggregation of
such protein “nanoparticles” might “breed”
the conformation true (nonmatching shapes
will be energetically unfavorable).
Domain Swapping
A separate way to generate fibrils and
oligomers is by “domain swapping,”29,30
in which, say, two identical copies (A,B) of
a protein exchange a domain (a well-defined
protein region attached to a flexible sec-
tion of peptide). The domain of monomer
A binds to the corresponding region of B
and vice versa. The swapping is not lim-
ited to dimers; it can lead to filamentary
structures in which the ith protein swaps
with the (i + 1)th protein, for example,
closed-chain oligomers (where filament
ends are brought together to domain-
swap) or two-dimensional structures.
Domain swapping has been proposed
to play a role in prion strains.31 Domain
swapping in protein–protein interactions
generically and amyloid diseases in par-
ticular seems certain to emerge as a critical
theme in the coming years. At the concep-
tual level, the study of coarse-grained pro-
tein models with molecular dynamics has
shown that the formation of domain-
swapped dimers will proceed down a
funneled landscape if the dimer enjoys
minimal frustration.
Aggregation Pathways and
Kinetics
AFM and kinetic modeling, well known
to materials scientists, have been instru-
mental in advancing our understanding
of the structural properties of the protein
aggregates linked to disease and their
growth kinetics. Figure 4 schematically
shows accepted models on amyloid con-
version/aggregation kinetics. We note
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Figure 2. (a) Peptide backbone of measured left-handed β-helix (LHBH) structure of 1FWY
protein. (b) Proposed LHBH structure of infectious prion protein (after Reference 16).
Parallel, hydrogen-bonded β-sheets are shown as strips. (c) Superposed structure of six
LHBH backbones, illustrating the uniform cross section of the helical structure (red, 1FWY
protein; blue, proposed infectious prion protein; yellow, 1HMO protein; white, 1J2Z protein;
green, 1L0S protein; fuchsia, 1T3D protein). (d) LHBH “nanotube” formed from a stack of
three 1FWY helices. All images generated with the RASTOP molecular viewing program
(see www.geneinfinity.org/rastop/); all files for the proteins 1FWY, 1HMO, 1J2Z, 1L0S, and
1T3D input to RASTOP are from the Protein Data Bank (http://www.rcsb.org), except for
the PrPSc model, which is courtesy of C. Govaerts. 
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that β-sheet conversion is typically con-
comitant with aggregation (i.e., conforma-
tional changes and protein assembly are
linked),32,33 with the possible exception of
polyglutamine proteins,34 and requires
templating either by spontaneously formed
(and rare) nuclei or by external seeding of
aggregates.33 Also, fission of mammalian
prions is necessary for disease propagation
and exponentially growing aggregates in
mammals; prion-like proteins in yeast
have fission effected by another protein35
(although the fission can occur sponta-
neously in vitro).36 Why mammalian prions
fission and other amyloidogenic proteins
do not remains a mystery.
In vitro and theoretical studies of con-
version/aggregation suggest that the late-
age onset in amyloid diseases derives from
slow underlying molecular processes. For
example, in vitro kinetics experiments for
polyglutamine peptides extrapolated to in
vivo concentrations of huntingtin protein
suggest that within the “sampling win-
dow” of a human lifespan, toxic aggregate
concentrations should arise only for gluta-
mine number p ! 36, consistent with clin-
ical observations.34
For prion diseases, theoretical modeling
of two-dimensional aggregation and fis-
sion (prions live mostly on neuronal
membranes) yielded a sporadic incuba-
tion time distribution that peaked at !100
times that obtained from dilute seeding
for physiological concentrations of the
normally expressed protein called PrPc
that misfolds in the diseased form.37
Given a mean incubation time for 
kuru of 12 years,38 this suggests that en-
demic sporadic prion disease requires
!1000-year life spans! Meanwhile, the 1 in
106 sporadic disease background inci-
dence may reflect the low-amplitude, 
pre-peak tail in the incubation time 
distribution.38
Amyloid–Membrane Interaction
and Toxicity
Many amyloidogenic proteins associate
with lipid membranes. AFM studies on
supported bilayers and molecular model-
ing have helped support a potential unify-
ing hypothesis for amyloid disease
toxicity: that small oligomers pierce cell
membranes, triggering cell death through
superfluous ion pores. It was proposed in
detail that a pair of β-coupled annular
tetramers of Aβ peptides can insert into
the neuronal membrane leaflets and create
an ion pore.39 In vitro-grown oligomers
qualitatively consistent with this hypothe-
sis have been found (Figure 3) and studied
with AFM on supported bilayers (Fig-
ure 3f); these are evidently composed of
4 nm spherical oligomers, much larger
than the peptide tetramers of Refer-
ence 39. These oligomers permit excess
calcium flux, which is toxic to cultured
neurons.26 Intracerebral inoculation of rats
and mice with a solution presumed rich in
oligomeric Aβ particles leads to a re-
versible short-term memory deficit.40 A
recent theoretical study found strong cor-
relations between the membrane insertion
configuration and the pore model for 4 
of 5 mutations leading to early-onset
Alzheimer’s disease.41 While the pore
model is not universally accepted, and
may not apply to all the diseases (the
prion trimer model, for example, will not
allow ion passage), it remains a vibrant
area of research.
Amyloids for Good in Biology and
Materials Science
Biologically Useful Amyloids
Emerging evidence suggests that amy-
loid structures can provide useful biologi-
cal functions. Some examples are
1. Heritable amyloid structure in yeast. As 
alluded to previously, prion-like proteins
in yeast form aggregates that fission 
upon cell division, can actively confer
phenotype, and may provide some stress
protection.42
2. Spider silk. Spiders produce insoluble fil-
aments of fibroin protein that possess 30×
greater extensibility and toughness than
steel. Recent circular dichroism studies
show that significant amyloid-like cross-β
structure develops in a region of reduced
The Materials Science of Protein Aggregation
Figure 3. Amyloid oligomers. (a) Aβ peptide implicated in Alzheimer’s disease, observed by
electron microscopy (scale, 50 nm/box) (from Reference 24). (b) Nine different oligomers of
mutant α-synuclein, implicated in Parkinson’s disease, observed by electron microscopy
(scale, 40.5 nm/box) (from Reference 25). (c) Six oligomers of mutant SOD1, implicated in
familial ALS (from Reference 56).57 (d) Nine mutant α-synuclein oligomers (scale, 40.5 nm/box)
(from Reference 25). (e) Atomic force microscope (AFM) images of Aβ oligomers inserted
in a supported lipid bilayer (from Reference 26). Clearly resolved annular oligomers have
outer diameters of !16 nm. (f) AFM image of α-synuclein oligomer on supported lipid
bilayer (from Reference 25). (g) Schematic illustration of oligomerization pathways. Here,
the subscript n in the second stage represents the number of monomers in an oligomer.
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pH downstream from the initial extrusion
site.43
3. Chorion in fish and insect egg shells. Trun-
cated peptides from the central regions of
two chorion proteins self-assembled into
spherulites possessing β-structure, which
then converted to fibrils upon maturation,
suggesting amyloid character in actual egg
shells.44
4. Amyloid-like structure in synapses of
Aplysia (slugs). The N-terminus region of
the Aplysia synapse protein CPEB is
glutamine-rich, like huntingtin protein.
Engineered expression of CPEB in yeast
yields prion-like aggregates similar to the
native ones discussed earlier; hence, prion-
like states of CPEB might effect long-term
strengthening of synaptic contacts.45
Amyloids in Materials Science
The regular diameter and periodicity of
the amyloid fibrils make them good mate-
rials templates. One group employed yeast
prion-like proteins to template !100-nm-
wide gold nanowire growth; the gold-
coated protein filaments after initial decor-
ation by small gold nanoparticles were
found to bind to genetically engineered
cysteine residues.46 Silver nanowires of
20 nm width were grown inside filamen-
tary cross-β tubes grown from a dipheny-
lalanine peptide.47 Engineering of con-
trollably switched β-sheet materials could
prove valuable for tissue growth scaffold-
ing, as one example.48 Hybrid molecules
including eight amino acids—four per
strand, but with non-amino bends—have
been developed that controllably self-
assemble into different β-sheet structures
(as shown in Figure 5) depending upon
the pH, analogous to spider silk.49 Clearly,
the future of engineered amyloid struc-
tures in materials science looks bright.50
Conclusion
In this article, we have developed
themes that bring together the fields of
amyloid diseases and materials science.
Protein misfolding and aggregation phe-
nomena are intimately linked to many se-
rious public health issues. However, many
aspects of the phenomena have close
analogies in synthesized materials, and
their full molecular understanding re-
quires experimental and modeling tools
more familiar in the physical and mate-
rials sciences. In addition to the possible
medical breakthroughs that such multi-
disciplinary studies can lead to, there is 
a growing possibility that understand-
ing the mechanisms of amyloid formation
can have wide impact in fields ranging
from basic neurobiology to materials 
science.
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Figure 4. Schematic illustration of amyloid conversion and aggregation. Native monomers of
the relevant peptides or proteins are shown as circles and high-β-content converted
proteins as squares. Peptides can either spontaneously convert or be seeded. Subsequent
aggregation and conversion can generate either proto-fibrils via the elongation step, which
then form amyloid fibrils and plaques, or pass to “off-pathway” oligomers. In the case of
prions, the oligomers and/or fibrils can fission, which then re-seeds the initial
conversion/aggregation process. Prions are the only known amyloid proteins to
spontaneously fission in the converted form either in vitro or in vivo. It is assumed (but not
shown explicitly here) that both oligomers and native monomers experience some level of
removal by cellular systems in vivo.
Figure 5. (a)–(c) Images from electron microscopy showing pH-dependent fibril growth of designed peptidomimetic molecules (from
Reference 49). Scale bars are 100 nm.
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